-
-
-
-
-
-
-
Dynavax Reports First Quarter 2022 Financial Results
-
-
-
-
-
-
-
Dynavax Announces Second Quarter 2021 Financial Results
-
-
-
-
-
-
-
Dynavax (DVAX) HEPLISAV-B Recommended by CDC Advisory Committee on Immunization Practices for Prevention of Hepatitis B in Adults
-
-
-
-
-
-
-
Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults
-
-
-
-
-
-
-
Pre-Open Stock Movers 07/31: (DVAX) (CHTR) (DAN) Higher; (HTZ) (CLVS) (ICPT) Lower (more...)
-
-
-
-
-
-
-
Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
-
-
-
-
-
-
-
Dynavax Receives Complete Response Letter from U.S. Food and Drug Administration for Biologics License Application for HEPLISAV-B
-
13,128 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All